Each year, consumers spend over $3B to prevent or treat influenza. The government spends $1.2B in research and pandemic prevention alternatives. No one has a solution that is effective at preventing seasonal flu, or mitigating the risk of a pandemic flu outbreak. Vaccines cannot be made to handle the ever-changing seasonal mutations across all the influenza strain variations. In addition, 40% of the population is opposed to, or unable to handle, shots or vaccines. A different approach is needed – a mechanism to put influenza into submission.

FluTrends is a therapeutics company that specializes in the treatment and prevention of influenza. Our desired outcome is to virtually eliminate the threat of influenza just as Jonas Salk virtually eliminated the threat of Polio in the mid 1950’s. We seek to change the devastating impact that results from a pandemic flu outbreak as well as reduce the cyclical economic loss caused by seasonal influenza throughout the world.

FluTrends designs and manufactures products for the $5B per year market to diagnose, prevent or treat influenza. Using patented technology, FluTrends takes a different approach to solving the influenza problem. The product line technology is not vaccine based. It uses a multilayered approach to leverage a different action mechanism that though administered directly to the point of entry and a major point of vulnerability—the throat and the nose. Once swallowed, it acts systemically on the virus.